# DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

> **NCT07142278** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nuravax, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Alzheimer Disease
- Alzheimer Disease (AD)
- Preclinical Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** DUVAX 200 µg
- **BIOLOGICAL:** DUVAX 400 µg
- **BIOLOGICAL:** Placebo (Adjuvant only)

## Key facts

- **NCT ID:** NCT07142278
- **Lead sponsor:** Nuravax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-07-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142278, "DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07142278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*